ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BIAFW bioAffinity Technologies Inc

0.59
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
bioAffinity Technologies Inc NASDAQ:BIAFW NASDAQ Equity Warrant
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 0.59 0.01 0.65 0 23:29:50

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

07/09/2023 1:00pm

Business Wire


bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more bioAffinity Technologies Charts.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Institutional investors interested in arranging a meeting with bioAffinity Technologies management can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel or contact Tirth Patel at LHA at tpatel@lhai.com.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com.

bioAffinity Technologies Julie Anne Overton Director of Communications jao@bioaffinitytech.com

LHA Investor Relations Tirth T. Patel tpatel@lhai.com

1 Year bioAffinity Technologies Chart

1 Year bioAffinity Technologies Chart

1 Month bioAffinity Technologies Chart

1 Month bioAffinity Technologies Chart